Back

Inhibition of liver ApoC3 by GalNAc-conjugated siRNA RBD5044: first-in-human trial to evaluate the safety, pharmacokinetics (PK), and pharmacodynamic (PD) effects on atherogenic lipid profiles in heal

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: Novel insights into lipid-lowering pharmacotherapy Lipid-Lowering Agents ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Associate Professor Anders Gabrielsen

Ribocure Pharmaceuticals, Gothenburg (Sweden)

7 More presentations in this session

Presentation thumbnail
The differences in lipid lowering therapies and the LDL-C goal attainment in patients with ASCVD documented by cardiologists and general practitioners in Germany.
Professor O. Weingaertner (Jena, DE)
Abstract Slides Video
Presentation thumbnail
Icosapent ethyl reduces cardiovascular risk across apolipoprotein b and fasting triglyceride rich lipoprotein levels
Doctor W. Malick (New York City, US)
Abstract Slides Video
Presentation thumbnail
Efficacy and safety of quadruple-drug fixed-dose single-pill combination therapy for hypertension and dyslipidemia: a prospective, multicenter, observational study
Assistant Professor E. Park (Seoul, KR)
Abstract Slides Video
Presentation thumbnail
Long-term survival of heFH or ACS patients on PCSK9 targeted therapy based on the real-life data from poland
Professor M. Banach (Lodz, PL)
Abstract Slides Video
Presentation thumbnail
Safety and efficacy of obicetrapib in dyslipidemia: systematic review and meta-analysis
Mr A. Senk Juh (Logatec, SI)
Abstract Slides Video

Access the full session

Session thumbnail
Novel insights into lipid-lowering pharmacotherapy

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025
You may be interested in
thumbnail
Congress Presentation
RNA interference targeting hepatic angiopoietin-like protein 3 results in prolonged reductions in serum triglyceride and non-HDL cholesterol concentrations: first human results with ARO-ANG3
thumbnail
Congress Presentation
Relation of apolipoprotein C3 to risk of major adverse cardiovascular events and death after acute coronary syndrome on a background of optimized statin treatment
thumbnail
Congress Presentation
Icosapent ethyl reduces cardiovascular risk across apolipoprotein b and fasting triglyceride rich lipoprotein levels

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources